GANX:NASDAQGain Therapeutics, Inc. Analysis
Data as of 2026-09-27 - not real-time
$1.78
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $1.78, Gain Therapeutics, Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. It has lost 17.8% over the past 30 days. RSI sits at 47.0, which reads as neutral, and MACD momentum is bullish. Price has been bracketed by support at $1.69 and resistance at $1.97.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 304.5% above today's level.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 49.2%, a beta of 1.79 and a maximum drawdown of 62.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to sell, carrying 4/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 304.5% above today's level.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 49.2%, a beta of 1.79 and a maximum drawdown of 62.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to sell, carrying 4/10 conviction.
Top Market Events
Gain Therapeutics will present and hold meetings at the ROTH Healthcare Conference on September 29,
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 2.07
- MACD momentum is positive
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 2.07
- Analyst targets imply +304.5% versus the current price
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Analyst targets imply +304.5% versus the current price
- Negative return on equity of -268.3%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-3.3
ROE-268.30%
ROA-95.51%
Debt/Equity5.40
P/B Ratio6.8
Op. Cash Flow$-18952456
Free Cash Flow$-11136962
Industry P/E30.5
Technical Analysis
TrendBearish
RSI47.0
Support$1.69
Resistance$1.97
MA 20$1.79
MA 50$1.84
MA 200$2.07
MACDBullish
VolumeIncreasing
Fear & Greed Index94.88
Valuation
Target Price$7.20
Upside/Downside304.49%
GradeFair
TypeGrowth
Risk Assessment
Beta1.79
Volatility49.21%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.